Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 944-948, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-880297
ABSTRACT
Prostate cancer (PCa) has become one of the common malignant diseases in elderly men, and its incidence is increasing year by year. Apart from surgery, radiotherapy and chemotherapy, immunotherapy, as with the programmed death receptor-1 (PD-1) or the programmed death ligand-1 (PD-L1) inhibitor, is a most promising new strategy for the treatment of PCa. PD-1 and PD-L1 inhibitors restore the activity of T cells by blocking the PD-1/PD-L1 signaling pathway in tumor cells, reverse the mechanism of tumor immune escape, recover the immune system and directly kill tumor cells. This review focuses on the current progress in the studies of PD-1 and PD-L1 inhibitors in the treatment of PCa.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias de la Próstata
/
Transducción de Señal
/
Antígeno B7-H1
/
Receptor de Muerte Celular Programada 1
/
Inhibidores de Puntos de Control Inmunológico
/
Inmunoterapia
Límite:
Humanos
/
Masculino
Idioma:
Chino
Revista:
National Journal of Andrology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS